Table 2—

Change-from-baseline serum lipid levels and glycemic control parameters

PlaceboRagaglitazar
Pioglitazone
0.1 mg1 mg4 mg10 mg45 mg
Lipid parameters (percent change  from baseline)
 Triglycerides5% (28)−12.6% (24)−40.4% (27)*−61.7% (29)*−51.4% (27)*−39.7% (24)*
 FFAs4.2% (29)−26.1% (25)*−36.1% (28)*−54.2% (31)*−61.8% (30)*−31.0% (26)*
 Apolipoprotein B−1.6% (18)2.9% (19)−13.3% (13)*−28.7% (22)*−25.2% (21)*−2.9% (21)
 LDL cholesterol0.2% (20)10.1% (21)−5.4% (23)−13.8% (31)*−19.0% (25)*11.6% (22)
 HDL cholesterol2.7% (29)5.3% (25)19.8% (28)*30.6% (31)*10.2% (29)15.1% (26)
 Total cholesterol1.4% (29)4.6% (25)−3.6% (28)−15.5% (31)*−14.8% (30)*1.4% (26)
Glycemic parameters (absolute  change from baseline)
 A1C (% units)0.8 (27)0.5 (22)−0.5 (27)*−1.3 (28)*−1.1 (24)*−0.3 (24)*
 FPG (mg/dl)22.5 (28)−9.3 (24)*−48.3 (26)*−74.1 (29)*−77.0 (27)*−43.1 (24)*
 Fructosamine (μmol/l)12.2 (27)11.1 (22)−25.9 (24)*−47.9 (27)*−35.3 (21)*−44.1 (24)*
 Fasting insulin (μU/ml)1.0 (25)−1.7 (21)−5.0 (24)*−6.8 (26)*−7.9 (26)*−4.3 (24)*
  • Data are least squares means, with changes calculated by the LOCF (last observation carried forward) method, and the number in parentheses represents the number of samples analyzed.

  • *

    * Significantly different from placebo (P < 0.05).